Embecta Corp. (EMBC)
6.27
-0.18
(-2.79%)
USD |
NASDAQ |
Oct 16, 16:00
6.285
+0.02
(+0.24%)
After-Hours: 20:00
Embecta Research and Development Expense (Annual) : 21.50M for Sept. 30, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| September 30, 2025 | 21.50M |
| September 30, 2024 | 78.80M |
| September 30, 2023 | 85.20M |
| September 30, 2022 | 65.00M |
| Date | Value |
|---|---|
| September 30, 2021 | 63.00M |
| September 30, 2020 | 61.00M |
| September 30, 2019 | 62.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Artivion, Inc. | 30.99M |
| Abbott Laboratories | 2.889B |
| AngioDynamics, Inc. | 29.45M |
| Alphatec Holdings, Inc. | 76.27M |
| AtriCure, Inc. | 90.17M |